Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Kyverna Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Kyverna Therapeutics, Inc.

KYTX

Kyverna Therapeutics, Inc.

About Kyverna Therapeutics, Inc.

Kyverna Therapeutics is a biopharmaceutical company developing cell therapies, primarily CAR T-cell products, to treat autoimmune diseases. Its lead candidate, KYV-101, targets B-cell-driven conditions like stiff person syndrome, myasthenia gravis, and lupus nephritis, aiming for durable remission through deep B cell depletion. The company leverages proprietary technologies, strategic partnerships, and innovative manufacturing to address unmet medical needs in autoimmune therapeutics.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Kyverna Therapeutics, Inc.

1
1
Kyverna Therapeutics, Inc. Kyverna Therapeutics Reports $39.7M Net Loss in Q1 2026, Decreases Operating Expenses

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Kyverna Therapeutics, Inc. Kyverna Therapeutics Reports $161.3 Million Net Loss for 2025 Amid Increased R&D Expenses

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Kyverna Therapeutics, Inc. Kyverna Therapeutics Reports Q3 2025 Financial Results with Increased Losses and Cash Decrease

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Kyverna Therapeutics, Inc. Kyverna Therapeutics Reports $42.1 Million Net Loss in Q2 2025, Increases Investment in Clinical Trials

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Kyverna Therapeutics, Inc. Kyverna Therapeutics Reports $44.6 Million Net Loss in Q1 2025 Amid Increased R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Kyverna Therapeutics, Inc. Kyverna Therapeutics Reports $127.5M Net Loss for 2024, Driven by Increased R&D Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Kyverna Therapeutics, Inc. Kyverna Therapeutics Reports Significant Financial Developments, Including Increased Cash Reserves and Operating Expenses

Via official filing (AI summary) | over 1 year ago | 0 comments